Lunch Symposium: Immuno-Oncology for GI Cancers: A Clinical Perspective on Current and Future Practice Supported by Bristol Myers Squibb
11:15 – 12:45 CEST
Lunch Symposium: Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise, Organised by PeerVoice, Supported by Taiho Oncology and Servier
11:15 – 12:45 CEST
Lunch Symposium: Novel Approaches for GI Cancers: Targeted Therapy for KRAS Mutations Supported by Mirati Therapeutics, Inc.
O-1: Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients metastatic pancreatic ductal adenocarcinoma: sensitivity analysis of survival from the NAPOLI 3 trial
Locally Advanced Bile Duct Cancer: Criteria and Approaches in Borderline Resectable Disease
Speaker: Thomas Gruenberger, MD – Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna
Sigmund Freud Private University Vienna
17:55 – 18:05 CEST
O-2: Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)